Atrogin-1 and MuRF1 regulate cardiac MyBP-C levels via different mechanisms

Giulia Mearini1, Christina Gedicke1, Saskia Schlossarek1, Christian C. Witt2, Elisabeth Krämer1, Peirang Cao3, Marcelo D. Gomes4, Stewart H. Lecker3, Siegfried Labeit2, Monte S. Willis5, Thomas Eschenhagen1, and Lucie Carrier1,6,7*

1Institute of Experimental and Clinical Pharmacology and Toxicology, University Medical Center Hamburg-Eppendorf, Martinistraße 52, D-20246 Hamburg, Germany; 2Institute of Anesthesiology and Operative Intensive Medicine, University of Mannheim, Mannheim, Germany; 3Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA; 4Department of Biochemistry and Immunology, Faculty of Medicine Ribeirão Preto, University of São Paulo, São Paulo, Brazil; 5Carolina Cardiovascular Biology Center, University of North Carolina, Chapel Hill, NC, USA; 6Inserm, U974, Institut de Myologie, Paris F-75013, France; and 7Université Pierre et Marie Curie-Paris 6, UMR-5974, CNRS, UMR7215, Institut de Myologie, IFR14, Paris F-75013, France

Received 15 May 2009; revised 16 October 2009; accepted 19 October 2009; online publish-ahead-of-print 22 October 2009

Time for primary review: 21 days

Aims
Familial hypertrophic cardiomyopathy (FHC) is frequently caused by cardiac myosin-binding protein C (cMyBP-C) gene mutations, which should result in C-terminal truncated mutants. However, truncated mutants were not detected in myocardial tissue of FHC patients and were rapidly degraded by the ubiquitin-proteasome system (UPS) after gene transfer in cardiac myocytes. Since the diversity and specificity of UPS regulation lie in E3 ubiquitin ligases, we investigated whether the muscle-specific E3 ligases atrogin-1 or muscle ring finger protein-1 (MuRF1) mediate degradation of truncated cMyBP-C.

Methods and results
Human wild-type (WT) and truncated (M7t, resulting from a human mutation) cMyBP-C species were co-immunoprecipitated with atrogin-1 after adenoviral overexpression in cardiac myocytes, and WT-cMyBP-C was identified as an interaction partner of MuRF1 by yeast two-hybrid screens. Overexpression of atrogin-1 in cardiac myocytes decreased the protein level of M7t-cMyBP-C by 80% and left WT-cMyBP-C level unaffected. This was rescued by proteasome inhibition. In contrast, overexpression of MuRF1 in cardiac myocytes not only reduced the protein level of WT- and M7t-cMyBP-C by 60%, but also the level of myosin heavy chains (MHCs) by 40%, which were not rescued by proteasome inhibition. Both exogenous cMyBP-C and endogenous MHC mRNA levels were markedly reduced by MuRF1 overexpression. Similar to cardiac myocytes, MuRF1-overexpressing (TG) mice exhibited 40% lower levels of MHC mRNAs and proteins. Protein levels of cMyBP-C were 29% higher in MuRF1 knockout and 34% lower in TG than in WT, without a corresponding change in mRNA levels.

Conclusion
These data suggest that atrogin-1 specifically targets truncated M7t-cMyBP-C, but not WT-cMyBP-C, for proteasomal degradation and that MuRF1 indirectly reduces cMyBP-C levels by regulating the transcription of MHC.

Keywords
E3 ubiquitin ligase • Sarcomere • Myosin-binding protein C • MuRF1 • Atrogin-1

1. Introduction
Familial hypertrophic cardiomyopathy (FHC) is an autosomal-dominant disease characterized by left ventricular (LV) hypertrophy and myocardial disarray.1,2 It is often referred to as a sarcomeropathy since it is associated with mutations in at least 13 genes encoding sarcomeric proteins (reviewed in Richard et al.2). Gene modifiers also contribute to the phenotype3,4 One of the most frequently mutated FHC genes is MYBPC3 encoding cardiac myosin-binding protein C (cMyBP-C).5 cMyBP-C is a major component of the A-band of the sarcomere and interacts with myosin, actin, and titin (for review, see Carrier6). It contains immunoglobulin- and fibronectin-like domains and it contains at least three phosphorylation sites in the MyBP-C motif. Most of

* Corresponding author. Tel: +49 40 7410 57208; fax: +49 40 7410 55925. E-mail: l.carrier@uke.uni-hamburg.de
Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2009. For permissions please email: journals.permissions@oxfordjournals.org
the MYBPC3 mutations are frameshift and should produce C-terminal truncated proteins.\textsuperscript{5,7,8} However, in myocardial tissue of FHC patients, there was no trace of the truncated proteins.\textsuperscript{9–12}

Previous data have shown that truncated cMyBP-Cs and an E344K cMyBP-C are rapidly and quantitatively degraded by the ubiquitin-proteasome system (UPS) after gene transfer in neonatal rat cardiac myocytes (NRCM), HeLa, or COS cells.\textsuperscript{13–15}

The UPS is the major degradation system of damaged, misfolded, or mutated proteins in eukaryotic cells (for review, see Ciechanover\textsuperscript{16}). The signal for protein degradation is the covalent attachment of ubiquitin, a small 76-amino acid protein, to the target protein, which is then degraded by the 26S proteasome complex. Polyubiquitination involves the concerted action of three enzymes: E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3 (ubiquitin ligase), the latter affording substrate specificity. Several muscle-specific E3 ubiquitin ligases have been identified (for review, see Mearini et al.\textsuperscript{17}). Among them, atrogin-1/MAFbx and the muscle ring finger proteins (MuRFs) are of particular interest since they are located in the sarcomere. Whereas MuRF1 is mainly located in the M-band but also at the Z-band, atrogin-1 and MuRF3 are restricted to the Z-band.\textsuperscript{18–22} MuRF1 has also been observed in nuclei.\textsuperscript{20} The expression of atrogin-1 and MuRF1 is up-regulated in skeletal muscle atrophy,\textsuperscript{23–26} and in experimental heart failure,\textsuperscript{27,28} but down-regulated in unloading-induced cardiac atrophy in rat.\textsuperscript{28}

Although atrogin-1 targets calcineurin A for proteasomal degradation,\textsuperscript{22} MuRF1 degrades cardiac troponin I, myosin heavy chain (MHC), and muscle creatine kinase.\textsuperscript{29–32} Recent data suggest that MuRF1 may also inhibit protein translation.\textsuperscript{33} Both atrogin-1 and MuRF1 blunt the development of cardiac hypertrophy in mice and/or in NRCM.\textsuperscript{22,34,35}

In the present study, we investigated whether the E3 ubiquitin ligases atrogin-1 or MuRF1 regulate the level of wild-type (WT) or truncated cMyBP-C (M7t), which results from a human FHC mutation and has been shown to be degraded by the UPS in NRCM.\textsuperscript{14} To address this question, adenoviral gene transfer in NRCM and mice deficient in MuRF1 (MuRF1-KO) or overexpressing MuRF1 (MuRF1-TG) were investigated. We show that atrogin-1 and MuRF1 regulate the level of WT and/or M7t-truncated cMyBP-C via different mechanisms.

2. Methods

An expanded material and methods section is given in the Supplementary material online.

All experiments involving animals were conform to the Guide for the Care and Use of Laboratory Animals published by the National Institute of Health (NIH) (Publication No. 85-23, revised 1985) and were approved by the University of North Carolina Institutional Animal Care Advisory Committee and the Regierungspräsidium Tübingen, Germany.

2.1 MuRF1-KO and MuRF1-TG mice

MuRF1-KO and MuRF1-TG mice have been described previously.\textsuperscript{33,36} LV mass index was calculated from echocardiography measurements performed with a Vevo 660 ultrasound system (VisualSonics Inc.) equipped with a 30 MHz transducer as described previously.\textsuperscript{35}

2.2 Generation of recombinant adenoviruses

Each adenovirus was constructed in the same way and encodes the protein of interest plus the EGFP in a bicistronic manner under the control of independent CMV promoters (Figure 1A). The adenovirus encoding myc-tagged human full-length cMyBP-C (myc-WT-cMyBP-C), human C-terminal truncated cMyBP-C (myc-M7t-cMyBP-C), and mouse MuRF1 (myc-MuRF1) were generated previously.\textsuperscript{14,37} The adenovirus encoding 6-myc-tagged mouse atrogin-1 (myc-atrogin-1) was constructed with the Ad-Easy system.\textsuperscript{38} In brief, mouse atrogin-1 cDNA was PCR-amplified and subcloned into BglII and XbaI sites of pAdTrack-CMV. The pAdTrack vector bearing atrogin-1 was electrotransfected into Escherichia coli BSJ183-AD1 (Stratagene) to produce adenoviral DNA through recombination. This DNA was transfected into 293A cells and viral plaques expressing atrogin-1 were selected and amplified in 293A cells using standard adenoviral techniques.

2.3 Immunofluorescence analysis

NRCM were fixed and proceeded for immunofluorescence as described previously.\textsuperscript{39,40} See Supplementary material online for details.

2.4 Western blot analysis

Total cardiac proteins were extracted from mouse ventricles or from myocyte lysates as described previously.\textsuperscript{41} See Supplementary material online for details.

2.5 Chymotrypsin-like activity assay

The chymotrypsin-like activity of the proteasome was assessed in ventricular cytosolic lysates using the synthetic peptide substrate SLLVY linked to the fluorogenic reporter aminomethylcoumarin (Calbiochem) as described previously.\textsuperscript{42} See Supplementary material online for details.

2.6 Statistical analysis

Data are expressed as mean ± SEM. Statistical analyses were performed using the unpaired Student’s t-test with the commercial software GraphPad Prism 4. A value of P < 0.05 was considered statistically significant.

3. Results

3.1 Atrogin-1 specifically targets truncated M7t-cMyBP-C for proteasomal degradation in cardiac myocytes

We previously showed that myc-M7t-truncated cMyBP-C is rapidly degraded by the UPS after gene transfer in NRCM.\textsuperscript{14} Treatment of myc-M7t-infected NRCM with different proteasome inhibitors stabilized myc-M7t levels and revealed higher M W myc-positive bands (Figure 1B), suggesting polyubiquitination and degradation of myc-M7t by the UPS. The localization of exogenous proteins was determined by immunofluorescence (Figure 1C). Myc-WT-cMyBP-C was incorporated into the A-band of the sarcomere as shown by the alternation of myc and Z-band-titin stainings (Figure 1C). In contrast, myc-M7t-cMyBP-C, which lacks the myosin-interacting domains (Figure 1A), was located in the Z-band of the sarcomere as shown by the localization of myc and Z-band-titin stainings (Figure 1C). Atrogin-1 was localized in both the nucleus and the Z-band of the sarcomere, where it showed alternation with cMyBP-C. The localization of both myc-M7t and atrogin-1 at the...
**Figure 1**

(A) Schematic representation of the adenovirus vectors containing the cDNA of interest and EGFP cDNA under the control of distinct CMV promoters, and schematic structure of the proteins encoded by the adenovirus: human full-length cMyBP-C (myc-WT-cMyBP-C), human C-terminally truncated cMyBP-C (myc-M7t-cMyBP-C), mouse atrogin-1 (myc-atrogin-1), and mouse MuRF1 (myc-MuRF1). The absence of exon 6 in myc-M7t-cMyBP-C results in a frameshift, loss of the terminal 1055 residues including the MyBP-C motif (PPP), and additional 41 novel amino acids (black box).

(B) Effect of proteasome inhibitors on the expression of myc-M7t in NRCM. NRCM were infected with myc-M7t adenovirus in the absence (Ctr) or presence of the proteasome inhibitors MG132 (132; 1 μM), MG262 (262; 100 nM), or epoxomicin (epo; 500 nM) for 24 h. Western blot (right panel) was stained with the anti-myc antibody and left panel shows the corresponding Ponceau. (C) Immunofluorescence staining and confocal microscopy of NRCM 24 h after infection with adenovirus. Myocytes were double-stained with an anti-myc antibody (green) and with the anti-titin (Z1 domain, red) or anti-cMyBP-C antibody (C0C1 domains; red). Arrowheads show aggregates.
Z-band suggests that atrogin-1 could interact with M7t-cMyBP-C and mediate M7t-cMyBP-C degradation by the UPS.

To determine whether atrogin-1 interacts with M7t-cMyBP-C, NRCM were co-infected with adenovirus encoding atrogin-1 and with either myc-M7t-cMyBP-C or myc-WT-cMyBP-C in the presence or absence of 1 μM MG132 for 24 h. Immunoprecipitation (IP) of the NRCM lysates treated with MG132 was performed with 0.8 μg anti-atrogin-1 antibody (+) or without antibody (−), and western blot (WB) was revealed with anti-atrogin-1 and anti-myc antibodies. P0 and SN correspond to the crude fraction and the supernatant after IP. Western blot of cell lysates (20 μg) was stained with the anti-ubiquitin antibody that recognizes a smear of ubiquitinated proteins (between 50 and 250 kDa), the anti-myc antibody for detection of exogenous myc-M7t-cMyBP-C (32 kDa), myc-WT-cMyBP-C (150 kDa), and myc6-atrogin-1 (52 kDa), and the anti-GFP antibody for loading control (GFP, 29 kDa). (C) Quantification of M7t and WT-cMyBP-C levels normalized to Ponceau in the absence (upper bars) or presence (lower bars) of MG132. Values are expressed as mean ± SEM. ***P < 0.001 vs. absence of atrogin-1, Student’s t-test. The number of experiments is indicated in the bars.

We then analysed whether atrogin-1 affects the levels of M7t- and WT-cMyBP-C after infection in NRCM. Treatment with MG132 increased the amount of ubiquitinated proteins in both Ad-M7t- and Ad-WT-infected cells, with or without Ad-atrogin-1, validating the inhibition of the proteasome (Figure 2B). In addition, MG132 significantly increased the amount of both M7t-cMyBP-C and atrogin-1, but not of WT-cMyBP-C. Strikingly, the level of M7t-cMyBP-C was 80% lower with atrogin-1 than without (compare lanes 1 and 3), and this was prevented by proteasome inhibition (Figure 2B and C). In contrast to M7t, the level of

---

Figure 2 Effect of atrogin-1 on the levels of WT/M7t-cMyBP-C after gene transfer in NRCM. NRCM were co-infected with myc6-atrogin-1 and with either myc-M7t-cMyBP-C or myc-WT-cMyBP-C in the presence or absence of 1 μM MG132 for 24 h. (A) Immunoprecipitation (IP) of the NRCM lysates treated with MG132 was performed with 0.8 μg anti-atrogin-1 antibody (+) or without antibody (−), and western blot (WB) was revealed with anti-atrogin-1 and anti-myc antibodies. P0 and SN correspond to the crude fraction and the supernatant after IP. (B) Western blot of cell lysates (20 μg) was stained with the anti-ubiquitin antibody that recognizes a smear of ubiquitinated proteins (between 50 and 250 kDa), the anti-myc antibody for detection of exogenous myc-M7t-cMyBP-C (32 kDa), myc-WT-cMyBP-C (150 kDa), and myc6-atrogin-1 (52 kDa), and the anti-GFP antibody for loading control (GFP, 29 kDa). (C) Quantification of M7t and WT-cMyBP-C levels normalized to Ponceau in the absence (upper bars) or presence (lower bars) of MG132. Values are expressed as mean ± SEM. ***P < 0.001 vs. absence of atrogin-1, Student’s t-test. The number of experiments is indicated in the bars.
WT-cMyBP-C was not altered with atrogin-1. GFP levels did not significantly differ in all conditions. The mRNA levels of WT- and M7t-cMyBP-C were not affected by atrogin-1 (see Supplementary material online, Figure S1A). These data suggest that truncated M7t and atrogin-1 are degraded by the UPS and that atrogin-1 targets M7t-cMyBP-C, but not WT-cMyBP-C for proteasome-mediated degradation.

3.2 MuRF1 indirectly reduces exogenous cMyBP-C levels in cardiac myocytes

Since WT-cMyBP-C is located in the A-band of the sarcomere and therefore around MuRF1, mainly located in the M-band of the sarcomere,\(^{20}\) we then investigated whether MuRF1 regulates the level of WT-cMyBP-C.

Immunoprecipitation with the anti-MuRF1 antibody did not work under our experimental conditions, thus we evaluated whether MuRF1 interacts with cMyBP-C by yeast two-hybrid screens, using an MuRF1 cDNA as a bait to screen an adult heart cDNA library. A total of four interacting clones identified cMyBP-C by sequencing (data not shown). The region of overlap between the different prey clones was found in the C7–C10 domains of cMyBP-C (Figure 3A). This suggests that MuRF1 can regulate the level of WT-cMyBP-C, but likely not of truncated M7t, which does not contain domains C7–C10 (Figure 1A).

We then investigated whether MuRF1 regulates the level of cMyBP-C after infection of NRCM with adenovirus encoding MuRF1 and WT- or M7t-cMyBP-C in the presence or absence of MG132 (Figure 3B and C). The protein levels of M7t- and WT-cMyBP-C were 86 and 66% lower with MuRF1 than without, respectively (Figure 3B and C). Of note, however, the effect of MuRF1 on the level of both cMyBP-C isofoms was not prevented by proteasome inhibition. Unexpectedly, MuRF1 reduced by >80% the mRNA levels of exogenous M7t- and WT-cMyBP-C (see Supplementary material online, Figure S2), but not the level of endogenous GAPDH and cMyBP-C (data not shown). MG132 markedly increased the steady-state levels of ubiquitinated proteins in the absence of MuRF1, but only slightly in the presence of MuRF1 (see Supplementary material online, Figure S2). GFP levels did not significantly differ in any condition. We then investigated whether MuRF1 could affect the expression of MHC, which has been shown to be degraded by MuRF1.\(^ {32,43}\) Surprisingly, the mRNA levels of \(\alpha\)-MHC and \(\beta\)-MHC were markedly lower in the presence of MuRF1 and were associated with lower MHC protein amount (see Supplementary material online, Figure S3). These data suggest that MuRF1 (i) does not directly target exogenous cMyBP-C for proteasome degradation and (ii) regulates the transcription of MHC. The strong transcriptional regulation by MuRF1 could explain the absence (or minor) effect of MG132 on the accumulation of MHC, cMyBP-C, and ubiquitinated proteins.

3.3 MuRF1 indirectly regulates the level of cMyBP-C in mice

To investigate whether MuRF1 regulates the level of cMyBP-C in the whole animal, we used an MuRF1-KO mouse and an MuRF1-TG mouse that overexpress MuRF1.\(^ {33,36}\) MuRF1-KO mice were created by homologous recombination and insertion of a Neo cassette in exon 2 (see Supplementary material online, Figure S4A).\(^ {33}\) The genotype of the animals was determined by PCR on genomic tail DNA with primers located around the Neo cassette (see Supplementary material online, Figure S4B). The absence of MuRF1 in the KO was confirmed by nonsense mRNA amplified by RT-qPCR with primers located in exons 1 and 3 and by western blot analysis with an antibody directed against the C-terminal part of MuRF1 (see Supplementary material online, Figure S4C). MuRF1-KO mice appeared normal in all aspects and were viable. The heart-weight-to-body-weight ratio did not differ in 24-week-old KO and WT mice (see Supplementary material online, Figure S4D). MuRF1-TG mice were created by overexpression of the mouse MuRF1 cDNA under control of the \(\alpha\)-MHC promoter (see Supplementary material online, Figure S4E).\(^ {36}\) Overexpression of MuRF1 was confirmed by real-time RT-qPCR and western blot analysis (see Supplementary material online, Figure S4F and G). The LV mass-to-body-weight did not differ in 8- to 12-week-old MuRF1-TG and WT mice (see Supplementary material online, Figure S4H).

We then investigated whether the absence or overexpression of MuRF1 results in alterations of the UPS in general and of cMyBP-C levels in particular. The absence of MuRF1 did not affect the steady-state levels of ubiquitinated proteins (Figure 4A) or the chymotrypsin-like activity of the proteasome (Figure 4B) compared with WT. It was also not associated with a compensatory increase in MuRF2, MuRF3, and atrogin-1 mRNAs (Figure 4C). In MuRF1-TG mice, the steady-state levels of ubiquitinated proteins were slightly higher than in WT (Figure 5A), and the chymotrypsin-like activity of the proteasome (Figure 5B) and mRNA levels of MuRF2, MuRF3 and atrogin-1 were unaltered (Figure 5C).

Importantly, the protein level of cMyBP-C was 29% higher in MuRF1-KO (Figure 6A) and 34% lower in MuRF1-TG (Figure 6B) than in WT littermates. This difference was even more pronounced in neonatal mice, where cMyBP-C levels were 150% higher in MuRF1-KO than in WT (see Supplementary material online, Figure 5). Similar levels of cMyBP-C mRNA were found in MuRF1-KO or MuRF1-TG compared with respective WT littermates (Figure 6C), suggesting a post-transcriptional regulation of the expression of cMyBP-C by MuRF1 in vivo. Similar to NRCM, MuRF1 overexpression in transgenic mice resulted in >35% lower levels of MHC (mainly \(\alpha\)-MHC) mRNAs and proteins (see Supplementary material online, Figure 6). This supports the view that MuRF1 may target an MHC-specific transcription factor. In contrast to MHC, the protein levels of cTnl, also known to be degraded by MuRF1,\(^ {37}\) were not affected in MuRF1-KO or MuRF1-TG mice (see Supplementary material online, Figure 7).

4. Discussion

We have previously shown that a truncated form of cMyBP-C resulting from a human MYBPC3 mutation (M7t-cMyBP-C) is rapidly and quantitatively degraded by the UPS after gene transfer in cardiac myocytes.\(^ {34}\) Since the diversity and specificity of the UPS regulation lie in the E3 ubiquitin ligases, we reasoned that identifying the E3 ubiquitin ligases involved in the degradation of cMyBP-C would represent an important first step to unravel the mechanisms
of the UPS-mediated regulation of cMyBP-C. We examined whether the E3 ubiquitin ligases atrogin-1 and MuRF1 affect the level of M7t-cMyBP-C and also WT-cMyBP-C. The major findings of the present study were: (i) atrogin-1 interacted with both cMyBP-C isoforms and targeted truncated M7t-, but not WT-cMyBP-C for UPS-mediated degradation in infected NRCM, (ii) two-hybrid screens identified cMyBP-C as an interacting partner of MuRF1, (iii) MuRF1 overexpression decreased the protein and mRNA levels of both WT- and M7t-cMyBP-C in NRCM, (iv) the absence of MuRF1 was associated with higher cMyBP-C levels in mice, and (v) overexpression of MuRF1 with lower cMyBP-C levels in mice. Our data also provide evidence that MuRF1 regulates the transcription of MHC both in cardiac myocytes and in mice.

The E3 ubiquitin ligases are directly or indirectly involved in the transfer of ubiquitin moieties to the proteins, which will be further degraded by the 26S proteasome (for review see Mearini et al.17). Co-expression of an E3 ubiquitin ligase and its target was expected to result in degradation of the target by the proteasome. Among several known muscle-specific E3 ubiquitin ligases, we focussed...
on atrogin-1 and MuRF1, both being located in the sarcomere. Our data support the view that atrogin-1 is an E3 ubiquitin ligase for M7t-cMyBP-C. First, atrogin-1 and M7t-cMyBP-C are both located in the Z-band of the sarcomere. Thus, the principal prerequisite for interaction is given. Secondly, co-immunoprecipitation assays identified M7t as an interaction partner of atrogin-1. Thirdly, atrogin-1 reduced the level of M7t protein, but not of M7t mRNA, and proteasome inhibition prevented this effect after gene transfer in cells. The effect of overexpressed atrogin-1 appeared to be restricted to the truncated M7t mutant. The lack of effect of atrogin-1 on WT-cMyBP-C is apparently not due to an inability to physically interact under the conditions of adenoviral overexpression, but rather the consequence of different localizations in the sarcomere making a direct interaction under normal conditions unlikely. Thus, co-immunoprecipitation of WT-cMyBP-C with atrogin does not prove de facto interaction in living cells.

In contrast to atrogin-1, MuRF1 reduced the levels of both WT- and M7t-cMyBP-C in infected cells and of endogenous cMyBP-C in the whole animal. Although this may suggest that MuRF1 is an E3 ubiquitin ligase for cMyBP-C, several results presented in this study do not support this view. First, the yeast two-hybrid screens identified the C7–C10 domains of cMyBP-C as an MuRF1-interacting region, but these domains are not present in M7t being downregulated similar to WT-cMyBP-C. Secondly, proteasome inhibition did not rescue the effect of MuRF1 on WT- and M7t-cMyBP-C levels in infected cells, in contrast to the results obtained with atrogin-1. Thirdly, mRNA levels of exogenous cMyBP-C were lower in the MuRF1-overexpressing myocytes. If MuRF1 is not a major E3 ubiquitin ligase for cMyBP-C, by which mechanisms does it regulate cMyBP-C? MuRF1 can affect gene expression via interaction with transcriptional modulators such as GMEB-1. This is supported by recent data showing that up-regulation of MuRF1 during muscle atrophy not only reduced the protein levels, but also the mRNA levels of MyBP-C. However, our data argue against transcriptional regulation of cMyBP-C by MuRF1, because it did not affect endogenous cMyBP-C mRNA levels neither in NRCM nor in transgenic mice, but only reduced exogenous cMyBP-C mRNAs derived from cDNAs in infected NRCM. MuRF1 could thus indirectly inhibit protein translation by down-regulating factors involved in translation initiation or elongation such as shown for INT-6.
alternative mechanism could be that MuRF1 indirectly reduces the protein level of cMyBP-C by regulating the transcription of MHC. Indeed, the levels of MHC mRNAs were markedly lower in MuRF1-overexpressing cells or mice, suggesting that MuRF1 degrades an MHC-specific transcription factor. Knowing that the stoichiometry of the sarcomere proteins is tightly regulated by co-translational and co-assembly mechanisms, lower level of MHC is likely associated with lower amount of cMyBP-C and vice versa. We therefore propose that the unexpected lower level of exogenous cMyBP-C mRNAs in MuRF1-infected NRCM is secondary to the lower transcription of MHC, in order to maintain the stoichiometry of the thick filament’s proteins.

Under the in vivo conditions in mice, loss or surplus of MuRF1 was not associated by changes in other MuRFs or global chymotrypsin-like activity, suggesting that MuRF1 does not markedly affect the global UPS function, but rather specifically the turnover of a few specific substrates. In contrast to previous data obtained after gene transfer in cells, but in agreement with other in vivo data, cTnI was not regulated by MuRF1 in mice, suggesting that cTnI is not a major target for MuRF1. Finally, we show that MG132 increased the level of atrogin-1 in NRCM, indicating that the E3 ligase atrogin-1 itself is a target for UPS-mediated degradation. Interestingly, the level of atrogin-1 was 42% lower in MuRF1-TG than in WT littermates (see Supplementary material online, Figure S8) without change in the mRNA levels, suggesting that MuRF1 could also target atrogin-1 for UPS-mediated degradation.

MuRF1 deletion or overexpression in mice did not alter the degree of LV hypertrophy but recent findings showed dilated

Figure 5 Investigation of the UPS in MuRF1-TG mice. (A) Representative western blot stained with the anti-ubiquitin antibody, corresponding Ponceau and steady-state level of ubiquitinated proteins (normalized to Ponceau) in ventricular tissue from 8- to 12-week-old WT and MuRF1-TG mice. (B) Chymotrypsin-like activity of the proteasome in WT and TG ventricular tissue. (C) mRNA levels of MuRF2, MuRF3, and atrogin-1 determined by RT-qPCR with specific Taqman probes and normalized to GAPDH. Bars represent the mean ± SEM. *P < 0.05 vs. WT, Student’s t-test. The number of animals is indicated in the bars.
cardiomyopathy with reduced myocyte cross-sectional area in MuRF1-TG mice.36 The reduced level of both MHC and cMyBP-C could contribute to this phenotype. Similar to our data, previous experiments with another MuRF1-KO mouse model showed no basal phenotype either, but increased sensitivity to TAC-induced cardiac hypertrophy,37 suggesting that the defect becomes apparent only after induction of cardiac stress.

In conclusion, our data suggest that MuRF1 plays an indirect role in the regulation of the expression of cMyBP-C, probably by targeting a transcription factor specific for MHC. Moreover, the present data suggest that atrogin-1 specifically acts as an E3 ubiquitin ligase for truncated M7t-cMyBP-C, resulting from a human MYBPC3 mutation. Further analyses are needed to investigate whether atrogin-1 is critical for the removal of truncated cMyBP-C mutants in mice and to which extent this process may contribute to the pathophysiology of FHC.

**Supplementary material**

Supplementary material is available at Cardiovascular Research online.

**Acknowledgements**

We thank Nessan Herrgesell, Denise Juhr, and Silke Reischmann (Hamburg) for active involvement in parts of the experiments.

**Conflict of interest:** none declared.

**Funding**

This work was supported by the Sixth Framework Program of the European Union (Marie Curie EXT-014051), the Deutsche Forschungsgemeinschaft (FOR-604/1-2, CA 618/1-2 to T.E. and L.C., WI 3278/2-1 to C.C.W.), and the Association Française contre les Myopathies (AFM-9471).

**References**


